Sage Therapeutics Inc.

Company Overview

Established in 2010 and headquartered in Cambridge, Mass., SAGE Therapeutics is a pharmaceutical organization committed to the improvement of health and quality of life of patients with central sensory system and related disorders. SAGE Therapeutics’ objective is to find, create and convey novel medicines for the patients disabled by central sensory system disorders through the use of innovative science. 

SAGE Therapeutics engages in the development and manufacturing of a wide range of medicines to treat the patients with CNS disorders. The company’s proprietary compounds focus on the N-methyl-d-aspartate (NMDA) and gamma-aminobutyric acid (GABA) receptor frameworks. In these frameworks, dysfunction is known to be at the center of various neurological issues. SAGE is dedicated to creating cutting-edge modulators, including SAGE-217 and SAGE-718, in different central nervous system disorders. Its top product is the Zulresso (brexanolone) injection for patients suffering from postpartum depression.

Financial Highlights (FY 2024)

Company's Business Segments

• Central Nervous System (CNS) & Brain Disorders : The company offers robust portfolio of drug candidates and therapies being developed for disorders of the brain and CNS.